Drugs / BNT111
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02410733 | Mar 2015 → Jun 2023 | melanoma | BioNTech SE | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04526899 | May 2021 → Jan 2024 | melanoma | BioNTech SE | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-07-30 | BioNTech SE | BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma biontech.com ↗ |
| 2021-11-19 | BioNTech SE | BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma biontech.com ↗ |
| 2021-06-18 | BioNTech SE | BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma biontech.com ↗ |
| 2020-07-30 | BioNTech SE | BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature biontech.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT111 | “We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are...” PMID 32728218 ↗ Jul 2020 |
| Known as | melanoma FixVac | “We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are...” PMID 32728218 ↗ Jul 2020 |
| Modality | Vaccine | “liposomal RNA (RNA-LPX) vaccine” PMID 32728218 ↗ Jul 2020 |
| Route | Intravenous | “intravenously administered” PMID 32728218 ↗ Jul 2020 |
| Target | TPTE | “targeting the Tumor-associated Antigens NY-ESO-1, Tyrosinase, MAGE-A3, and TPTE” NCT02410733 ↗ |